
www.ESHO.info



COUNCIL: G.C. van Rhoon (The Netherlands), GJ van Tienhoven (The Netherlands), O. Ott (Germany), T.L.M. ten Hagen (The Netherlands), V. Kouloulias (Greece), M.R. Horsman (Denmark), S. Dall'Oglio (Italy), L. Lindner (Germany), M. Persson (Sweden).

Date: July 1st 2014 tel: +31 (0)10 7041806

Reference: - fax: +31 (0)10 7041022

Subject: Policy ESHO 2014-2019 e-mail: g.c.vanrhoon@erasmusmc.nl

The European Society for Hyperthermic Oncology (ESHO) is registrated at the Dutch Chamber of Commerce, Amsterdam, The Netherlands under number KvK 40537174 and is recognized by the Dutch Ministry of Finance as Public Benefit Organisation" (Dutch: Algemeen Nut Beogende Instelling, ANBI), registration number 805406219 (RSIN/fiscal number).

The board consists of the following nine persons

- 1. G.C. van Rhoon, The Netherlands, president
- 2. M.R. Horsman, Denmark, secretary/treasurer
- 3. GJ van Tienhoven, The Netherlands
- 4. O. Ott, Germany
- 5. T.L.M. ten Hagen, The Netherlands
- 6. V. Kouloulias, Greece
- 7. S. Dall'Oglio, Italy
- 8. L. Lindner, Germany
- 9. Mikael Persson, Sweden

As stipulated below the Board members perform all activities for the ESHO board voluntary, they receive no payment.

The objects for which the Society is established are (see also the statutes elsewhere on the web-site):

- A. To carry out the following aims (hereinafter called "the primary objects") namely, to promote for the public benefit, fundamental and applied research in physics, engineering, biological and clinical sciences relating to the use of hyperthermia in cancer therapy.
- B. To facilitate integration and exchange of information between different disciplines in the study of the biological effects of heat in the treatment of cancer either alone or combined with other cancer treatment modalities.

Below we provide our work policy and plans for the period of 2014 to 2019. The financial statement of 2012 is also provided at the end of this document. The financial statement of 2013 is currently reviewed by the accountant.

ESHO policy document for 2014-2019.


In compliance with the objectives as presented in detail in the Statutes of the European Society for Hyperthermic Oncology, the activities of the society for the five year period 2014-2019 will address the following items:

Scientific Promotion

- ESHO annual scientific meetings will be organised in 2014 in Turin, Italy, 2015 in Aarau, Switzerland, 2017 in Athens, Greece, 2018 in Poland. The location for the 2019 annual meeting will be decided on in due course. Important issues for each meeting will be the promotion of hyperthermia as an important modality to enhance the effectiveness of radiotherapy and chemotherapy.

President: Dr. G.C. van Rhoon, Erasmus MC, Dept. of Radiation Oncology, Hyperthermia Unit, Groene Hilledijk 301, 3075 EA Rotterdam, The Netherlands,

www.ESHO.info



COUNCIL: G.C. van Rhoon (The Netherlands), GJ van Tienhoven (The Netherlands), O. Ott (Germany), T.L.M. ten Hagen (The Netherlands), V. Kouloulias (Greece), M.R. Horsman (Denmark), S. Dall'Oglio (Italy), L. Lindner (Germany), M. Persson (Sweden).

For ESHO it is beneficial if at each annual meeting a part of the scientific symposium or a workshop session can be organized with affiliated societies, such that a win-win situation will exist and the combined activity will strengthen all involved societies.

- In 2016 ESHO will refrain from an annual scientific meeting. Instead ESHO will participate in the Internal Conference on Hyperthermia in Oncology (ICHO) as organized under the auspices of the three major continental hyperthermia societies, i.e. ESHO, Society for Thermal Medicine (STM) and the Asian Society for Hyperthermic Oncology (ASHO). STM is the representative society for all types of treatments associated with thermal medicine (thermal ablation, hyperthermia, cryotherapy, long duration mild whole body) in the United States of America. The ASHO is the coordinating society of all Asian orientated hyperthermia society, like those active in Japan, Korea, India and China. The ICHO 2016 international meeting will be organized by the STM and is planned for April 10-15th, 2016, in New Orleans, USA.
- In addition all ESHO members, but especially ESHO board members will actively promote hyperthermia by making contributions (presentations, posters etc) at other oncology and medical technology orientated scientific meetings.

Exchange of knowledge

- Yearly three ESHO board members will be elected as the Public Relation committee. They will be responsible for the ESHO web-page and the ESHO newsletter.
- A new, interactive ESHO web-page is foreseen for 2015. The new web-page should provide all relevant information for a general audience looking for information on the use of hyperthermia in cancer treatment, ongoing clinical trials and medical/academical centers that provide evidence based hyperthermia treatments.
- The intention is to distribute an ESHO newsletter four times a year. The newsletter will be emailed to all ESHO members and others with an interest in hyperthermia. The newsletter will provide actual information on all activities of ESHO and associated sister organisations, literature reviews and summaries, active and upcoming clinical trials, introduce new hyperthermia centers etc.
- ESHO will continue to consider the International Journal of Hyperthermia as the only official society journal and promote its members to submit their scientific manuscripts to this journal.

Society membership


- Currently ESHO has around 170 members from all over Europe. It is the aim of the society to expand
 the number of members to around 300 members. Special attention will be put on the accrual of new
 members in countries with a low number of members such as France, Greece, Poland, United
 Kingdom. In addition the cooperation with associated societies for high intensity ultrasound will
 actively pursued for combined activities such as annual meetings, workshop etc.
- Companies can only become an ESHO member through a corporate membership. All companies active within the field of oncology will be offered a corporate membership to ESHO. The additional income of this activity will be used for the support of the ESHO web page.

Clinical research

- To further extend wide acceptance of hyperthermia as an important modality in the treatment cancer, undisputable clinical evidence from international, multi-institutional randomized trials is an absolute requirement. To stimulate the implementation of new trials ESHO will continue to support the Atzelsberg Clinical Circle. This Circle is a multi-disciplinary forum at which medical specialist of all medical discipline meet together with physicists and biologist to discuss new clinical trials.
- ESHO is also the authority to contact the various medical authorities in the European countries involved in the official registration and recognition of new modalities for cancer treatments.

President: Dr. G.C. van Rhoon, Erasmus MC, Dept. of Radiation Oncology, Hyperthermia Unit, Groene Hilledijk 301, 3075 EA Rotterdam, The Netherlands,

www.ESHO.info



COUNCIL: G.C. van Rhoon (The Netherlands), GJ van Tienhoven (The Netherlands), O. Ott (Germany), T.L.M. ten Hagen (The Netherlands), V. Kouloulias (Greece), M.R. Horsman (Denmark), S. Dall'Oglio (Italy), L. Lindner (Germany), M. Persson (Sweden).

Education

- With the growing number of medical centers applying hyperthermia the development of a strong education program is an important topic. In 2008 ESHO successfully organized the first school on hyperthermia. The second ESHO summer-school on hyperthermia is being prepared for 2014.
- To stimulate young investigators to actively participate in the annual meetings ESHO will continue granting at least three Young Investigators Awards (one for each discipline: medicine, biology, technology) at a level of € 500 each and accompanied by an official ESHO certificate. For ease of financing each Award will carry in addition to ESHO the name of the sponsoring company.
- ESHO will continue to grant one award of € 3000 per annum to recognize special scientific and societal merits of a senior ESHO member. Here again the Award will carry in addition to ESHO the name of the sponsoring company.

Fundraising


- The treasurer will be responsible to select the level of the membershipfee and to collect this fee from all members. ESHO has decided that the total income of the membershipfees must be sufficient to cover all regular running costs of ESHO.
- Special fundraising to companies, all European Cancer Charity foundation but also private Charity foundation will be contacted for financial sponsoring of the implementation of the essential clinical trials. From the fundraising achieved ESHO will sponsor only scientific activities that are needed for the active implementation and scientific analysis of such trails.
- Special fundraising will also be aimed at companies to obtain funds for the various ESHO awards.

Management of assets.

- ESHO will have only financial resources. It will not have any estate properties.
- All assets will only be used as stated in the statutes. ESHO-board members will not receive financial compensation for their efforts or participation to the annual meeting of ESHO. In exceptional cases ESHO will reimburse costs to the ESHO-board members for expenses they have made specifically for ESHO activities.
- The treasurer of ESHO will manage all ESHO assets as prescribed in the statutes, i.e. following a secure no/low risk policy.
- The accounts and the balance sheets of ESHO will be reported as prescribed by the statutes.
- ESHO will keep a financial reserve at the level of at least on annual meeting budget.
- In case of liquidation of ESHO all funds of ESHO will be donated to one or more scientific organisations active in the field of cancer research as stipulated in the statutes.

President: Dr. G.C. van Rhoon, Erasmus MC, Dept. of Radiation Oncology, Hyperthermia Unit, Groene Hilledijk 301, 3075 EA Rotterdam, The Netherlands,

www.ESHO.info



COUNCIL: G.C. van Rhoon (The Netherlands), GJ van Tienhoven (The Netherlands), O. Ott (Germany), T.L.M. ten Hagen (The Netherlands), V. Kouloulias (Greece), M.R. Horsman (Denmark), S. Dall'Oglio (Italy), L. Lindner (Germany), M. Persson (Sweden).

Financial statement 2012

K						ministratiekanto L. van Kan B.V.	
					ZiOi (tali		
A							
European Society for Hyper	thermic (Oncology					
Financial statement year 2012							
Accounts:		ar ended 31-12- amounts in EU					
	All	amounts in EO	NO .				
	_	2012		_	2011		
Income							
Senator Rosner Stiftung		100.000					
Dr. G. Sennewald Medizintechnik	2012	3.000		2011	6.000		
Annual meeting contribution	2012	-		2011	6.000		
Cash payment memberships							
Student Awards (ZMT, Alba, Magforc	e			2011	1.500		
Payment ICHO 2008	_	10.000					
	_	113.000		_	13.500		
Membership fees	2011	250		2011	8.554		
Membership fees	2012	9.548		2012	6.173		
Membership fees	2013	5.386					
Interest	2012	1.852		2011	1.206		
interest	2012	17.036		2011	15.933		
		17.030	130.036		15.955	29.43	
Less:							
Heta Study		100.000					
Publishing Taylor & Francis		9.959			10.043		
Office costs				2010	2.250		
Office costs	2012	1.045		2011	2.500		
Office costs	2012	1.043		2011	2.500		
ESHO-BSD Award	2012	6.000		2011			
ESHO Student Awards				2011	1.500		
ESHO Rossner Awards	2012	3.000					
Liposomen Workshop support					500		
Various		50			606		
Bank Charges		460			125		
		895			120		
Accountant		693	121.410			17.52	
Total wanning year			8.626			11.90	
Total running year			0.020			11.50	
Balance brought forward year before			83.280			71.37	
Balance to carry forward to next year			91.906			83.28	
Debtors							
Office costs			2.500				
Fund for ESHO school activities			13.000			6.00	
ICHO Fund			3.000				
Financial position			73.406			77.280	

President: Dr. G.C. van Rhoon, Erasmus MC, Dept. of Radiation Oncology, Hyperthermia Unit, Groene Hilledijk 301, 3075 EA Rotterdam, The Netherlands,